Pharma Industry
Industry: Email Alert RSS FeedStudy of talabostat and cisplatin in advanced melanoma
Journal of Drugs in Dermatology, Sept-Oct, 2005
This study is currently recruiting patients. Sponsored by Point Therapeutics. The purpose of this study is to assess the antitumor activity and safety of the combination of talabostat and cisplatin in patients with metastatic melanoma.
Condition Treatment or Intervention Phase Melanoma Drug: talabostat (PT-100) tablets Phase II Skin Cancer Drug: cisplatin
Study ID Numbers: PTH-303
Most RecentPharma Articles
- Noven's Brandt Pockets $2.4M in Hisamitsu Buy, Just 15 Months Into the Job
- Analysts Rain on Lilly's Effient Parade; 70% of Sales Go Generic After 2011
- Doctors May Not All Be Big Pharma's Friends in Healthcare Reform Debate
- UPDATED: Pfizer Accused of "Bribe" to Stave Off Price Control Law in Philippines
- Merck KGaA on Cancer Vaccines: We're Not Crazy, Just Convinced
- More »
ClinicalTrials.gov Identifier: NCT00083252
COPYRIGHT 2005 Journal of Drugs in Dermatology, Inc.
COPYRIGHT 2008 Gale, Cengage Learning
Brought to you by CBS MoneyWatch.com
- 10 Best Places to Retire
- Companies with the Best 401(k) Plans
- Most Important Document for Your Heirs? It's Not Your Will
- Video: Should You Expect to Retire Rich?
- Over 50? Here's How to Get (and Keep) a Great Job
Most Recent Health Articles
Most Recent Health Publications
Most Popular Health Articles
- Detox in 7 days: a detoux diet can help you shed up to 10 pounds and leave you feeling terrific. Our weeklong plan shows you how to lose the weight and keep it off - Cover story
- All about nightshades: explore the hidden hazards of your favorite food with macrobiotic nutritionist Lino Stanchich
- La anemia falciforme - causas y tratamiento
- The sour truth about apple cider vinegar - evaluation of therapeutic use
- Treat sinusitis naturally: breath easy and relieve sinus pressure with these remedies - Quick Fixes and Long-Term Solutions
Most Popular Health Publications
Content provided in partnership with
